Veraxa Biotech AG - Post de-SPAC
VRXA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0002079109
In the last 90 days, Veraxa Biotech AG - Post de-SPAC insiders filed 4 open-market purchases and 0 sales; 8 institutions reported holding it in 13F filings for Q2 2026, worth $599.6K in total; no superinvestor holds it.
Other share classesVRXAW
Key figures
- Market capNo recent share count in SEC filings
- –
- Insider buysLast 90 days, $125.3K in total
- 4
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +8 vs. previous quarter
- 8
- 13F valueReported value at the end of Q2 2026
- $599.6K
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 91.2K
- Shares sold short
- Change
- −16.2K
- −15.1% vs. previous
- Days to cover
- 1.00
- At average daily volume
Superinvestors holding VRXA, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding VRXA at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Veraxa Biotech AG - Post de-SPAC insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 29, 2026 (view filing)4:52 PM ET | Oct 27-28 | 2 days | Gruninger MarcDirector | PPurchase | +10.0K | $0.9983 | +$9.98K | New position10.0K after | 2 lots |
| Oct 21, 2026 (view filing)4:10 PM ET | Oct 20 | 1 day | Ziegler Christoph SamuelDirector | PPurchase | +30.0K | $1.09 | +$32.7K | +378.2%37.9K after | |
| Aug 31, 2026 (view filing)4:10 PM ET | Aug 27 | 4 days | Baumann Oliver RolfDirector | PPurchase | +50.0K | $1.50 | +$75.0K | +0.9%5.77M after | |
| Aug 31, 2026 (view filing)4:10 PM ET | Aug 27 | 4 days | Antz Christoph RudigerChief Executive Officer | PPurchase | +5.00K | $1.53 | +$7.65K | New position5.00K after |
Top 10 13F holders, Q2 2026
See all 8 holdersThe largest institutional positions in Veraxa Biotech AG - Post de-SPAC at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| UBS Group AG | 157,237 | $295.6K | 0.00% | +157,237 | New |
| Geode Capital Management, LLC | 119,767 | $225.2K | 0.00% | +119,767 | New |
| HRT Financial LP | 18,874 | $35.0K | 0.00% | +18,874 | New |
| Susquehanna International Group, LLP | 10,833 | $20.4K | 0.00% | +10,833 | New |
| Picton Mahoney Asset Management | 175,000 | $19.3K | 0.00% | +175,000 | New |
| Wolverine Asset Management LLC | 1,748 | $3.29K | 0.00% | +1,748 | New |
| JPMorgan Chase & Co | 396 | $859 | 0.00% | +396 | New |
| Caitong International Asset Management Co., Ltd | 6 | $11 | 0.00% | +6 | New |